首页> 外国专利> IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR, AND CYTOKINE RECEPTOR AGONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY

IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR, AND CYTOKINE RECEPTOR AGONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY

机译:疫苗和肿瘤免疫治疗中TNFRSF,TLR,NLR,RHR,消化道受体和细胞因子受体激动剂的免疫刺激组合

摘要

This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TNFRSF) agonists, Toll-Like Receptor (TLR) agonists, "domain present in NAIP,CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)" or "NLR" agonists, RIG-I-Like Helicase or "RLH" agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and/or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.
机译:本发明公开了肿瘤坏死因子受体超家族(TNFRSF)激动剂,Toll样受体(TLR)激动剂,“存在于NAIP,CIITA,HET-E,TP-1(NACHT)-亮氨酸富集重复序列(LRR)中的结构域”的免疫刺激组合。 ″或″ NLR″激动剂,RIG-I-类解旋酶或″ RLH″激动剂,嘌呤能受体激动剂和细胞因子/趋化因子受体激动剂,以及递送方法。当在病理部位单独使用时,这些组合可提供免疫刺激作用,诱导宿主的体液和细胞免疫反应,以消除病原体或肿瘤。可选择地,当组合与确定的抗原一起使用时,这些组合可以诱导集中的体液和细胞免疫应答,可用作感染和肿瘤性疾病的预防和/或改善的治疗方式。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号